Research & Literature

Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.

Wong-Brown MW, Meldrum CJ, Carpenter JE, et al.

Breast cancer research and treatment 2015; (150(1)):71-80 doi:10.1007/s10549-015-3293-7.

Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis.

Xu L, Zhao Y, Chen Z, et al.

Breast cancer (Tokyo, Japan) 2015; (22(4)):327-34 doi:10.1007/s12282-015-0619-6.

Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.

Metcalfe K, Lynch HT, Foulkes WD, et al.

JAMA oncology 2015; (1(3)):306-13 doi:10.1001/jamaoncol.2015.0658.

Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.

Desmond A, Kurian AW, Gabree M, et al.

JAMA oncology 2015; (1(7)):943-51 doi:10.1001/jamaoncol.2015.2690.

Population-Wide Screening for Germline BRCA1 and BRCA2 Mutations: Too Much of a Good Thing?

Yurgelun MB, Hiller E, Garber JE

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015; (33(28)):3092-5 doi:10.1200/JCO.2015.60.8596.

Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer.

Hirotsu Y, Nakagomi H, Sakamoto I, et al.

Molecular genetics & genomic medicine 2015; (3(5)):459-66 doi:10.1002/mgg3.157.

Next-Generation Gene Sequencing: Looking Beyond Hereditary Breast and Ovarian Cancer.

Estrada SS, LeGrazie B, McKamie T, Montgomery S

Oncology nursing forum 2015; (42(6)):691-4 doi:10.1188/15.ONF.691-694.

Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy.

Johansen N, Liavaag AH, Tanbo TG, et al.

Gynecologic oncology 2016; (140(1)):101-6.

The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.

Hartmann LC, Lindor NM

The New England journal of medicine 2016; (374(5)):454-68 doi:10.1056/NEJMra1503523.

Managing patients at genetic risk of breast cancer.

Pederson HJ, Padia SA, May M, Grobmyer S

Cleveland Clinic journal of medicine 2016; (83(3)):199-206 doi:10.3949/ccjm.83a.14057.

Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review.

Li X, You R, Wang X, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2016; (22(15)):3971-81 doi:10.1158/1078-0432.CCR-15-1465.

Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients.

George A, Riddell D, Seal S, et al.

Scientific reports 2016; (6()):29506 doi:10.1038/srep29506.

Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.

Kotsopoulos J, Huzarski T, Gronwald J, et al.

Journal of the National Cancer Institute 2017; (109(1)) doi:10.1093/jnci/djw177.

Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review.

Ludwig KK, Neuner J, Butler A, et al.

American journal of surgery 2016; (212(4)):660-669 doi:10.1016/j.amjsurg.2016.06.010.

CDC Grand Rounds: Family History and Genomics as Tools for Cancer Prevention and Control.

Rodriguez JL, Thomas CC, Massetti GM, et al.

MMWR. Morbidity and mortality weekly report 2016; (65(46)):1291-1294 doi:10.15585/mmwr.mm6546a3.

Pedigree and BRCA gene analysis in breast cancer patients to identify hereditary breast and ovarian cancer syndrome to prevent morbidity and mortality of disease in Indian population.

Darooei M, Poornima S, Salma BU, et al.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2017; (39(2)):1010428317694303 doi:10.1177/1010428317694303.

Therapeutic targeting and patient selection for cancers with homologous recombination defects.

Talens F, Jalving M, Gietema JA, Van Vugt MA

Expert opinion on drug discovery 2017; (12(6)):565-581 doi:10.1080/17460441.2017.1322061.

Impact of risk-reducing salpingo-oophorectomy in premenopausal women.

Vermeulen RFM, Beurden MV, Korse CM, Kenter GG

Climacteric : the journal of the International Menopause Society 2017; (20(3)):212-221 doi:10.1080/13697137.2017.1285879.

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.

Dougherty BA, Lai Z, Hodgson DR, et al.

Oncotarget 2017; (8(27)):43653-43661 doi:10.18632/oncotarget.17613.

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.

Kuchenbaecker KB, Hopper JL, Barnes DR, et al.

JAMA 2017; (317(23)):2402-2416 doi:10.1001/jama.2017.7112.

Practice Bulletin No. 182 Summary: Hereditary Breast and Ovarian Cancer Syndrome.

Obstetrics and gynecology 2017; (130(3)):657-659 doi:10.1097/AOG.0000000000002285.

The Role of PALB2 in the DNA Damage Response and Cancer Predisposition.

Nepomuceno TC, De Gregoriis G, de Oliveira FMB, et al.

International journal of molecular sciences 2017; (18(9)) doi:10.3390/ijms18091886.

Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers.

Harmsen MG, Piek JMJ, Bulten J, et al.

Cancer 2018; (124(5)):952-959 doi:10.1002/cncr.31211.

Male Breast Cancer: Epidemiology and Risk Factors.

Abdelwahab Yousef AJ

Seminars in oncology 2017; (44(4)):267-272 doi:10.1053/j.seminoncol.2017.11.002.

Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.

Kotsopoulos J, Gronwald J, Karlan B, et al.

Gynecologic oncology 2018; (150(1)):85-91 doi:10.1016/j.ygyno.2018.05.011.

Mechanisms of PARP inhibitor sensitivity and resistance.

D'Andrea AD

DNA repair 2018; (71()):172-176 doi:10.1016/j.dnarep.2018.08.021.

Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis.

Chen H, Wu J, Zhang Z, et al.

Frontiers in pharmacology 2018; (9()):909 doi:10.3389/fphar.2018.00909.

Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types.

Heeke AL, Pishvaian MJ, Lynce F, et al.

JCO precision oncology 2018; (2018()) doi:10.1200/PO.17.00286.

Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing.

Mersch J, Brown N, Pirzadeh-Miller S, et al.

JAMA 2018; (320(12)):1266-1274 doi:10.1001/jama.2018.13152.

Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls.

Momozawa Y, Iwasaki Y, Parsons MT, et al.

Nature communications 2018; (9(1)):4083 doi:10.1038/s41467-018-06581-8.

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

Lin KK, Harrell MI, Oza AM, et al.

Cancer discovery 2019; (9(2)):210-219 doi:10.1158/2159-8290.CD-18-0715.

Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.

Marchetti C, De Felice F, Boccia S, et al.

Critical reviews in oncology/hematology 2018; (132()):111-115 doi:10.1016/j.critrevonc.2018.09.018.

Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers.

Laitman Y, Michaelson-Cohen R, Levi E, et al.

Cancer 2019; (125(5)):698-703 doi:10.1002/cncr.31842.

Exome Sequencing-Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants.

Manickam K, Buchanan AH, Schwartz MLB, et al.

JAMA network open 2018; (1(5)):e182140 doi:10.1001/jamanetworkopen.2018.2140.

Contrast-enhanced MRI for breast cancer screening.

Mann RM, Kuhl CK, Moy L

Journal of magnetic resonance imaging : JMRI 2019; (50(2)):377-390 doi:10.1002/jmri.26654.

Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.

Gordhandas S, Norquist BM, Pennington KP, et al.

Gynecologic oncology 2019; (153(1)):192-200 doi:10.1016/j.ygyno.2018.12.014.

Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer.

Ohmoto A, Yachida S, Morizane C

International journal of molecular sciences 2019; (20(3)) doi:10.3390/ijms20030561.

Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance.

Abe T, Blackford AL, Tamura K, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(13)):1070-1080 doi:10.1200/JCO.18.01512.

Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.

Blok F, Dasgupta S, Dinjens WNM, et al.

Gynecologic oncology 2019; (153(2)):326-334 doi:10.1016/j.ygyno.2019.03.003.

The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.

Oh M, Alkhushaym N, Fallatah S, et al.

The Prostate 2019; (79(8)):880-895 doi:10.1002/pros.23795.

Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines.

Vermeulen RFM, Korse CM, Kenter GG, et al.

Climacteric : the journal of the International Menopause Society 2019; (22(4)):352-360 doi:10.1080/13697137.2019.1582622.

Women's cancers: how the discovery of BRCA genes is driving current concepts of cancer biology and therapeutics.

Murthy P, Muggia F

Ecancermedicalscience 2019; (13()):904 doi:10.3332/ecancer.2019.904.

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

Moore KN, Secord AA, Geller MA, et al.

The Lancet. Oncology 2019; (20(5)):636-648 doi:10.1016/S1470-2045(19)30029-4.

Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia.

Mahfoudh W, Bettaieb I, Ghedira R, et al.

Journal of translational medicine 2019; (17(1)):123 doi:10.1186/s12967-019-1873-8.

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer.

Ledermann JA, Pujade-Lauraine E

Therapeutic advances in medical oncology 2019; (11()):1758835919849753 doi:10.1177/1758835919849753.

Prevalence of Suspected Hereditary Cancer Syndromes and Germline Mutations Among a Diverse Cohort of Probands Reporting a Family History of Prostate Cancer: Toward Informing Cascade Testing for Men.

Chandrasekar T, Gross L, Gomella LG, et al.

European urology oncology 2020; (3(3)):291-297 doi:10.1016/j.euo.2019.06.010.

Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons.

Manahan ER, Kuerer HM, Sebastian M, et al.

Annals of surgical oncology 2019; (26(10)):3025-3031 doi:10.1245/s10434-019-07549-8.

Screening for Pancreatic Cancer.

Lucas AL, Kastrinos F

JAMA 2019; (322(5)):407-408 doi:10.1001/jama.2019.9690.

Metachronous or synchronous male breast and prostate cancers a duality to lookout for.

Mukendi AM, Van Den Berg E, Pather S, Padayachee RS

F1000Research 2018; (7()):1825 doi:10.12688/f1000research.16997.2.

Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

Nelson HD, Fu R, Zakher B, et al.

JAMA 2019; (322(9)):868-886 doi:10.1001/jama.2019.5780.

Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.

Nyberg T, Frost D, Barrowdale D, et al.

European urology 2020; (77(1)):24-35 doi:10.1016/j.eururo.2019.08.025.

Population prevalence of individuals meeting criteria for hereditary breast and ovarian cancer testing.

Greenberg S, Buys SS, Edwards SL, et al.

Cancer medicine 2019; (8(15)):6789-6798 doi:10.1002/cam4.2534.

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

González-Martín A, Pothuri B, Vergote I, et al.

The New England journal of medicine 2019; (381(25)):2391-2402 doi:10.1056/NEJMoa1910962.

Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome.

Yoo J, Lee GD, Kim JH, et al.

Annals of laboratory medicine 2020; (40(2)):148-154 doi:10.3343/alm.2020.40.2.148.

A dominant RAD51C pathogenic splicing variant predisposes to breast and ovarian cancer in the Newfoundland population due to founder effect.

Dawson LM, Smith KN, Werdyani S, et al.

Molecular genetics & genomic medicine 2020; (8(2)):e1070 doi:10.1002/mgg3.1070.

Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.

Su L, Xu Y, Ouyang T, et al.

International journal of cancer 2020; (146(12)):3335-3342 doi:10.1002/ijc.32918.

Is hormonal therapy after risk-reducing salpingo-oophorectomy associated with an increased risk of malignancy in pathogenic variant carriers?

Mills KA, Joshi TV, West L, et al.

Gynecologic oncology 2020; (157(3)):706-710 doi:10.1016/j.ygyno.2020.02.033.

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.

Daly MB, Pilarski R, Yurgelun MB, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2020; (18(4)):380-391.

BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects.

Wong W, Raufi AG, Safyan RA, et al.

Cancer management and research 2020; (12()):2731-2742 doi:10.2147/CMAR.S211151.

Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England.

Flaum N, Morgan RD, Burghel GJ, et al.

European journal of human genetics : EJHG 2020; (28(11)):1541-1547 doi:10.1038/s41431-020-0692-y.

Prevalence and molecular characteristics of DNA mismatch repair deficient endometrial cancer in a Japanese hospital-based population.

Yamamoto A, Yamaguchi T, Suzuki O, et al.

Japanese journal of clinical oncology 2021; (51(1)):60-69 doi:10.1093/jjco/hyaa142.

BRCA1/2 mutations and risk-reducing bilateral salpingo-oophorectomy among Latinas: The UPTAKE study.

Lynce F, Schlam I, Geng X, et al.

Journal of genetic counseling 2021; (30(2)):383-393 doi:10.1002/jgc4.1322.

Retrospective evaluation of risk-reducing salpingo-oophorectomy for BRCA1/2 pathogenic variant carriers among a cohort study in a single institution.

Kobayashi Y, Hirasawa A, Chiyoda T, et al.

Japanese journal of clinical oncology 2021; (51(2)):213-217 doi:10.1093/jjco/hyaa173.

Targeting the DNA Repair Enzyme Polymerase θ in Cancer Therapy.

Schrempf A, Slyskova J, Loizou JI

Trends in cancer 2021; (7(2)):98-111 doi:10.1016/j.trecan.2020.09.007.

How does genetic testing influence anxiety, depression, and quality of life? A hereditary breast and ovarian cancer syndrome suspects trial.

Oliveira FFB, de Barros Silva PG, de Sant'Ana RO, et al.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2021; (29(7)):3521-3530 doi:10.1007/s00520-020-05867-2.

Five Italian Families with Two Mutations in BRCA Genes.

Vietri MT, Caliendo G, D'Elia G, et al.

Genes 2020; (11(12)) doi:10.3390/genes11121451.

Molecular Features and Clinical Management of Hereditary Gynecological Cancers.

Ueki A, Hirasawa A

International journal of molecular sciences 2020; (21(24)) doi:10.3390/ijms21249504.

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Daly MB, Pal T, Berry MP, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2021; (19(1)):77-102.

Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes-Practice resource of the National Society of Genetic Counselors.

Berliner JL, Cummings SA, Boldt Burnett B, Ricker CN

Journal of genetic counseling 2021; (30(2)):342-360 doi:10.1002/jgc4.1374.

Interventions Facilitating Family Communication of Genetic Testing Results and Cascade Screening in Hereditary Breast/Ovarian Cancer or Lynch Syndrome: A Systematic Review and Meta-Analysis.

Baroutsou V, Underhill-Blazey ML, Appenzeller-Herzog C, Katapodi MC

Cancers 2021; (13(4)) doi:10.3390/cancers13040925.

Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.

Huber D, Seitz S, Kast K, et al.

Journal of cancer research and clinical oncology 2021; (147(7)):2035-2045 doi:10.1007/s00432-021-03629-z.

BRCA mutated pancreatic cancer: A change is coming.

Rosen MN, Goodwin RA, Vickers MM

World journal of gastroenterology 2021; (27(17)):1943-1958 doi:10.3748/wjg.v27.i17.1943.

BRCA1/2 signaling and homologous recombination deficiency in breast and ovarian cancer.

Royfman R, Whiteley E, Noe O, et al.

Future oncology (London, England) 2021; (17(21)):2817-2830 doi:10.2217/fon-2021-0072.

A competing risks model with binary time varying covariates for estimation of breast cancer risks in BRCA1 families.

Choi YH, Jung H, Buys S, et al.

Statistical methods in medical research 2021; (30(9)):2165-2183 doi:10.1177/09622802211008945.

Hereditary pancreatic cancer.

Abe K, Kitago M, Kitagawa Y, Hirasawa A

International journal of clinical oncology 2021; (26(10)):1784-1792 doi:10.1007/s10147-021-02015-6.

Replication-dependent cytotoxicity and Spartan-mediated repair of trapped PARP1-DNA complexes.

Saha LK, Murai Y, Saha S, et al.

Nucleic acids research 2021; (49(18)):10493-10506 doi:10.1093/nar/gkab777.

Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status.

Saravi S, Alizzi Z, Tosi S, et al.

Cells 2021; (10(9)) doi:10.3390/cells10092434.

Homologous recombination proficiency in ovarian and breast cancer patients.

Creeden JF, Nanavaty NS, Einloth KR, et al.

BMC cancer 2021; (21(1)):1154 doi:10.1186/s12885-021-08863-9.

Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis.

Vidra R, Nemes A, Vidrean A, et al.

Experimental and therapeutic medicine 2022; (23(1)):91 doi:10.3892/etm.2021.11014.

Impact of Variant Reclassification in Cancer Predisposition Genes on Clinical Care.

Chiang J, Chia TH, Yuen J, et al.

JCO precision oncology 2021; (5()):577-584 doi:10.1200/PO.20.00399.

Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women.

Kurian AW, Hughes E, Handorf EA, et al.

JCO precision oncology 2017; (1()):1-12 doi:10.1200/PO.16.00066.

Incidence and Prevalence of Intraductal Papillary Mucinous Neoplasms in Individuals With BRCA1 and BRCA2 Pathogenic Variant.

Shah I, Silva-Santisteban A, Germansky KA, et al.

Journal of clinical gastroenterology 2023; (57(3)):317-323 doi:10.1097/MCG.0000000000001683.

The BRCA Gene in Epithelial Ovarian Cancer.

Sánchez-Lorenzo L, Salas-Benito D, Villamayor J, et al.

Cancers 2022; (14(5)) doi:10.3390/cancers14051235.

"I have always lived with the disease in the family": family adaptation to hereditary cancer-risk.

Silva E, Gomes P, Matos PM, et al.

BMC primary care 2022; (23(1)):93 doi:10.1186/s12875-022-01704-z.

Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal.

Kotsopoulos J, Lubinski J, Gronwald J, et al.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2022; (31(7)):1351-1358 doi:10.1158/1055-9965.EPI-21-1196.

PARP Inhibition and Beyond in BRCA-Associated Breast Cancer in Women: A State-Of-The-Art Summary of Preclinical Research on Risk Reduction and Clinical Benefits.

Pauwels EKJ, Bourguignon MH

Medical principles and practice : international journal of the Kuwait University, Health Science Centre 2022; (31(4)):303-312 doi:10.1159/000525281.

Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.

Graffeo R, Rana HQ, Conforti F, et al.

Breast (Edinburgh, Scotland) 2022; (65()):32-40 doi:10.1016/j.breast.2022.06.003.

Germline Pathogenic Variant Prevalence Among Latin American and US Hispanic Individuals Undergoing Testing for Hereditary Breast and Ovarian Cancer: A Cross-Sectional Study.

Ossa Gomez CA, Achatz MI, Hurtado M, et al.

JCO global oncology 2022; (8()):e2200104 doi:10.1200/GO.22.00104.

Familial Pancreatic Cancer.

Saba H, Goggins M

Gastroenterology clinics of North America 2022; (51(3)):561-575 doi:10.1016/j.gtc.2022.06.006.

Genetic testing for patients at risk of hereditary breast and ovarian cancer.

DeTroye A, Gabbett K, Yi C, et al.

JAAPA : official journal of the American Academy of Physician Assistants 2022; (35(10)):48-52 doi:10.1097/01.JAA.0000873796.81961.da.

Evolving DNA repair synthetic lethality targets in cancer.

Kulkarni S, Brownlie J, Jeyapalan JN, et al.

Bioscience reports 2022; (42(12)) doi:10.1042/BSR20221713.

Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2.

Yadav S, Boddicker NJ, Na J, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(9)):1703-1713 doi:10.1200/JCO.22.01239.

Implementation of BRCA mutations testing in formalin-fixed paraffin-embedded (FFPE) samples of different cancer types.

Zannini G, Facchini G, De Sio M, et al.

Pathology, research and practice 2023; (243()):154336 doi:10.1016/j.prp.2023.154336.

Evaluation of genetic alterations in hereditary cancer susceptibility genes in the Ashkenazi Jewish women community of Mexico.

Díaz-Velásquez CE, Gitler R, Antoniano A, et al.

Frontiers in genetics 2023; (14()):1094260 doi:10.3389/fgene.2023.1094260.

BRCA carriers after risk-reducing bilateral salpingo-oophorectomy: menopausal hormone therapy knowledge gaps, and the impact of physicians' recommendations.

Armon S, Miron-Shatz T, Mor P, et al.

Climacteric : the journal of the International Menopause Society 2023; (26(2)):154-160 doi:10.1080/13697137.2023.2173567.

Clinical risk management of breast, ovarian, pancreatic, and prostatic cancers for BRCA1/2 variant carriers in Japan.

Ueki A, Yoshida R, Kosaka T, Matsubayashi H

Journal of human genetics 2023; (68(8)):517-526 doi:10.1038/s10038-023-01153-1.

Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.

Li N, Zhu J, Yin R, et al.

JAMA oncology 2023; (9(9)):1230-1237 doi:10.1001/jamaoncol.2023.2283.

Clinical features of germline BRCA1/2 or ATM pathogenic variant positive pancreatic cancer in Japan.

Kitamura H, Morizane C, Tanabe N, et al.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2023; (23(8)):964-969 doi:10.1016/j.pan.2023.10.017.

Unlocking Therapeutic Potential of Poly(Adenosine Diphosphate Ribose) Polymerase (PARP) Inhibitors in Metastatic Breast Cancer With BRCA Gene Mutations: A Narrative Review.

Jain P

Cureus 2023; (15(10)):e46405 doi:10.7759/cureus.46405.

Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.

Wei X, Sun L, Slade E, et al.

JAMA network open 2024; (7(2)):e2355324 doi:10.1001/jamanetworkopen.2023.55324.

Beyond BRCA: Review of Hereditary Syndromes Predisposing to Breast Cancer.

Nguyen JV, Thomas MH

Journal of breast imaging 2019; (1(2)):84-91 doi:10.1093/jbi/wbz014.

A case of hereditary breast and ovarian cancer syndrome of initially presented as cancer of unknown primary with lymph node metastases unveiled by genetic analysis.

Yamada J, Fukuda K, Sugawara T, et al.

International cancer conference journal 2024; (13(2)):139-143 doi:10.1007/s13691-023-00652-4.

Hereditary Cancer Syndrome Carriers: Feeling Left in the Corner.

Diez de Los Rios de la Serna C, Lluch-Canut MT, Fernández-Ortega MP

Seminars in oncology nursing 2024; (40(3)):151624 doi:10.1016/j.soncn.2024.151624.

Lynch syndrome in Mexican-Mestizo families: Genotype, phenotypes, and challenges in cascade testing among relatives at risk.

Rivero-García P, Chavarri-Guerra Y, Rodríguez Olivares JL, et al.

Heliyon 2024; (10(11)):e31855 doi:10.1016/j.heliyon.2024.e31855.

Incidence of endometrial cancer in BRCA mutation carriers.

Kotsopoulos J, Lubinski J, Huzarski T, et al.

Gynecologic oncology 2024; (189()):148-155 doi:10.1016/j.ygyno.2024.07.687.

Prostate cancer and genetic contributions.

Chou WH, Chalker C, Sokolova AO, Isharwal S

Andrology 2025; (13(5)):1149-1157 doi:10.1111/andr.13812.

Endoscopic innovations in diagnosis and management of pancreatic cancer: a narrative review and future directions.

Harne PS, Harne V, Wray C, Thosani N

Therapeutic advances in gastroenterology 2024; (17()):17562848241297434 doi:10.1177/17562848241297434.

Risk-benefits assessment of tamoxifen or raloxifene as chemoprevention for risk reduction of breast cancer among BRCA1 and BRCA2 carriers: a meta-analysis.

Alwashmi ASS, Khan NU, Chen T

Scientific reports 2025; (15(1)):6796 doi:10.1038/s41598-025-89915-z.

Exploring Breast Cancer Risk Management in HBOC Patients: Image Surveillance Versus Risk-reducing Surgery.

Seki T, Kobayashi Y, Masuda K, et al.

The Keio journal of medicine 2025; (74(3)):130-137 doi:10.2302/kjm.2024-0021-RE.

Pancreatic Cancer in Hereditary Breast and Ovarian Cancer Syndrome: Is Early Detection Possible?

Abe K, Kitago M, Kobayashi Y, et al.

The Keio journal of medicine 2025; (74(3)):146-150 doi:10.2302/kjm.2024-0018-OA.

Factors affecting the implementation of cascade testing of patients with BRCA1 or BRCA2 pathogenic germline variants in Japan.

Kiyozumi Y, Nishimura S, Kado N, et al.

Journal of genetic counseling 2025; (34(3)):e70055 doi:10.1002/jgc4.70055.

Expanding the Genomic Landscape of HBOC and Cancer Risk Among Mutation Carriers.

Vietri MT, Della Pepa C, Caliendo G, et al.

International journal of molecular sciences 2025; (26(13)) doi:10.3390/ijms26135928.

Reclassification of BRCA1 and BRCA2 Variants of Unknown Significance in a Turkish Cohort; A Single-Center, Retrospective Study.

Özer L, Aktuna S, Ünsal E

European journal of breast health 2025; (21(4)):295-300 doi:10.4274/ejbh.galenos.2025.2025-5-2.

Time trends, uptake, and oncological effects of risk-reducing surgeries in 3067 Danish BRCA1/2 carriers: a population-based study with matched controls.

Willert CB, Mellemkjær L, Tolver A, et al.

Breast cancer research and treatment 2025; (214(3)):355-366 doi:10.1007/s10549-025-07821-4.

Poly(ADP-ribose) polymerase-1 in breast cancers: expression level and its association in various molecular subtypes with a focus in Africa.

Yahaya JJ, Ngaiza AI

Discover oncology 2025; (16(1)):1767 doi:10.1007/s12672-025-03341-1.

Genetic education and peer support among Ashkenazi Jewish women in the United States at risk for and surviving with breast cancer.

Zamir T, Statman MR, Sleiman MM, et al.

Journal of genetic counseling 2025; (34(5)):e70121 doi:10.1002/jgc4.70121.

Improving genetic diagnosis of hereditary tumor syndromes: From expanded gene panels to functional genomics.

Sauer M, Lucas MC, Prokosch V, et al.

International journal of cancer 2025; doi:10.1002/ijc.70274.

Translational Aspects of DNA Damage Repair in Optimizing Cancer Chemotherapy.

Lin A, He J, Jiang A, et al.

Advanced genetics (Hoboken, N.J.) 2025; (6(4)):e00036 doi:10.1002/ggn2.202500036.